Massachusetts Final Budget: How the Act Will Affect Pharmaceutical Companies

August 23, 2019 Alerts and Newsletters

On July 31, 2019, Governor Charlie Baker signed a $43.3 billion fiscal year 2020 budget ("General Appropriations Act"). Originating from the Conference Committee's budget, the General Appropriations Act accounts for any vetoes by the Governor and any overrides by the Massachusetts House of Representatives ("House") and Senate. The House and Senate voted in favor of the Conference Committee's budget, H. 4000, on July 22, 2019, almost unanimously. Baker signed the General Appropriations Act 31 days after the new fiscal year began. Perhaps the most significant aspect of the General Appropriations Act for pharmaceutical companies is that it provides greater authority for MassHealth, the Commonwealth's Medicaid program, to negotiate supplemental rebates directly with pharmaceutical companies. Baker's proposed budget included even stronger prescription drug price controls to reduce MassHealth's costs, but these stronger controls did not make it into the General Appropriations Act.

General Appropriations Act

The General Appropriations Act allows MassHealth to directly negotiate with pharmaceutical companies for supplemental rebates on the prices of the most expensive prescription drugs used by MassHealth based on the prescription drug's value, efficacy, and outcomes. Before entering into supplemental rebate negotiations, MassHealth must first assess, however, if the pharmaceutical company currently offers discounts to MassHealth. A pharmaceutical company may request to enter into supplemental rebate negotiations with MassHealth, but MassHealth may decline or put other supplemental rebate negotiations first. MassHealth may hold a public rate-setting hearing to create a target value for the prescription drug if supplemental rebate negotiations between MassHealth and the pharmaceutical company fail and both sides cannot agree on a price for the prescription drug post-rebate that is less than $25,000 per individual per year or that results in more than $10 million cumulatively spent by MassHealth per year. MassHealth must give at least 30 days' notice of the hearing date to the pharmaceutical company and the public. If negotiations still fail after the public rate-setting hearing, MassHealth may refer the pharmaceutical company to the Health Policy Commission for an additional review in private. Prior to October 15 each year, MassHealth must report to the clerks of the House and Senate, the Joint Committee on Health Care Financing, and the House and Senate Committees on Ways and Means on the number of supplemental rebates received from pharmaceutical companies, the number of prescription drugs receiving a supplemental rebate categorized by pharmaceutical company, and an itemization of the period of the supplemental rebates received.

For assistance with questions regarding how your pharmaceutical company can navigate these new requirements, please reach out to James Roosevelt, Andrew Rusczek, or your regular Verrill attorney.

Firm Highlights

Publication/Podcast

The Regulatory Sprint is Over - What’s at the Finish Line Under the New Stark and AKS Final Rules?

The U.S. Department of Health and Human Services (HHS) completed its “Regulatory Sprint” by finalizing changes to regulations pertaining to two federal fraud and abuse laws. On December 2, 2020, the Centers for Medicare...

News

Verrill Welcomes Jeffrey A. Smagula, Experienced Health Care and Life Sciences Attorney, Former Health Plan Compliance Executive

(May 12, 2021) – Verrill is pleased to welcome Jeffrey A. Smagula to the firm’s Boston office as Counsel in its nationally recognized Health Care & Life Sciences Group. Jeff Smagula brings to Verrill...

Publication/Podcast

HHS Confirms Providers’ Right to 340B Discount Pricing for Contract Pharmacies

As a holiday gift to providers, the U.S. Department of Health and Human Services (HHS) General Counsel recently issued a strongly worded Advisory Opinion indicating that federal law requires drug manufacturers to deliver covered...

Publication/Podcast

“If I've told you once, I've told you eight times…” HHS OIG Issues Another Audit Report on Hospitals’ Failure to Report Credits for Explanted Cardiac Devices and Lays the Groundwork Collection of Overpayments

Publication/Podcast

Hospital Price Transparency Rule: Full Steam Ahead

Neither COVID-19 nor continued legal challenges appear likely to derail the Centers for Medicare & Medicaid Services ( CMS) Hospital Price Transparency Rule from going into effect on January 1, 2021. Hospitals therefore should...

News

65 Verrill Attorneys Recognized by Best Lawyers® 2022, Including Eight Named Lawyers of the Year

(August 31, 2021) – 65 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2022 , including 8 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer in...

Publication/Podcast

Massachusetts Health Care Bill Makes Several Significant Changes

While you were celebrating the New Year, Governor Baker signed Chapter 260 of the Acts of 2020, an “Act promoting a resilient health care system that puts patients first,” the result of the Legislature’s...

Publication/Podcast

Fraud and Abuse Investigations Handbook for the Health Care Industry, Second Edition.

Health care attorney Paul Shaw co-authored Fraud and Abuse Investigations Handbook for the Health Care Industry, Second Edition with Robert Griffith, published by the American Health Law Association (AHLA). Paul and Robert provide legal...

Publication/Podcast

340B Providers Get Partial Relief from New Dispute Resolution Regulation

1. 340B ADR Process Established At long last, more than ten years after Congress directed it to do so, HHS has finalized an alternative dispute resolution (“ADR”) process for both providers and pharmaceutical manufacturers...

Contact Verrill at (855) 307 0700